Learn More
Description
Gibco Recombinant Human (rHu) Insulin AOF is a high-purity, animal origin–free insulin supplement trusted by our scientists and validated through years of internal process development. Designed for advanced cell culture and bioproduction, it enables consistent, USP/EP regulatory-compliant performance in serum-free and chemically defined media.
Manufactured to Gibco quality standards, this insulin supports reliable, high-yield production of monoclonal antibodies, vaccines, viral vectors, recombinant proteins, and stem cell systems, helping ensure optimal performance from development through commercial scale.
Features of Gibco rHu Insulin AOF include:
- Supports cell growth and productivity across CHO, HEK293, Hybridoma, VERO, and stem cell systems
- Manufactured using a fully animal origin–free (AOF), GMP-compliant process to align with USP and EP regulatory expectations and minimize contamination sources
- Designed to promote lot-to-lot consistency, supporting reproducible bioproduction results
- Enables efficient scale-up with globally validated supply assurance and adherence to GMP principles.
- Adaptable to your process needs with customizable volumes and flexible packaging options
Gibco rHu Insulin AOF is produced using advanced recombinant DNA technology, helping ensure exceptional purity, performance stability, and elimination of animal-derived materials. It meets USP and EP grade standards, aligning with global regulatory expectations for therapeutic and vaccine manufacturing.
Validated over years by our media development teams, Gibco rHu Insulin AOF is manufactured under the same stringent Gibco quality and testing standards trusted by scientists globally. Its reliable global supply chain, documented traceability, and scalable production formats make it a low-risk, high-performance option for modern bioproduction without the complexities associated with animal-origin (AO) materials.
Bring Gibco validated performance into your own bioprocess. Contact us to learn how our high-value Gibco rHu Insulin AOF can help enhance your productivity and reduce process risk compared to AO-derived.
As a critical growth factor, insulin regulates glucose uptake and metabolism to promote strong cell viability, growth, and protein expression in serum-free and chemically defined systems. It is ideal for bioreactor-based antibody production (CHO, HEK, NS0, Hybridoma and myeloma cells), viral vector manufacturing (HEK293, VERO), and stem cell expansion, where consistency, purity, and low contamination risk are key.
For tailored solutions, our team offers custom packaging options designed to streamline your workflow and simplify integration into existing processes. Contact us to discuss how customized volumes, formats, and configurations of Gibco™ Recombinant Human Insulin AOF can optimize your production efficiency and reduce handling complexity.
Specifications
Specifications
| CAS | 11061-68-0 |
| Certifications/Compliance | USP, EP |
| Form | Powder |
| Product Type | Insulin |
| Sterility | Non-sterile |
| Endotoxin Level | <10 EU/mg, <0.1 EU/mL in a 10 mg/L Solution |
| Manufacturing Quality | GMP |
| Purity or Quality Grade | USP, EP; AOF |
| Quantity | 1 g |
| Reactivity | ≥27.5 U/mg |
| Show More |
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.